Development of a disability scale for myotonic dystrophy type 1

Acta Neurologica Scandinavica

Volumn 125, Issue 6, 2012, Pages 431-438

  Contardi, S ^a   Pizza, F ^a   Falzone, F ^a   D'Alessandro, R ^a   Avoni, P ^a   Di Stasi, V ^a   Montagna, P ^a   Liguori, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical scale; Mexiletine; Myotonic dystrophy type 1; Neuromuscular impairment

Indexed keywords

MEXILETINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BARTHEL INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; EPWORTH SLEEPINESS SCALE; FOLLOW UP; GRONINGEN ACTIVITY RESTRICTION SCALE; HUMAN; INSTRUMENTAL ACTIVITIES OF DAILY LIFE; MYOTONIA; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; MYOTONIC DYSTROPHY TYPE 1 DISABILITY SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLOGICAL DISABILITY SCORE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR IMPAIRMENT; RIVERMEAD MOBILITY INDEX;

ACTIVITIES OF DAILY LIVING; ADULT; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84860120145     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01587.x     Document Type: Article

References (36)

1. Machuca-tzili L, Brook D, Hilton-jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005;32:1-18.
2. Meola G, Moxley RT 3rd. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004;251:1173-82.
3. Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 2006;13:71-9.
4. Brook JD, Mccurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
5. Buxton J, Shelbourne P, Davies J, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992;355:547-8.
6. Fu Yh, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-8.
7. Harley HG, Brook JD, Rundle SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992;355:545-6.
8. The International Myotonic Dystrophy Consortium (IDMC). New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology 2000;54:1218-21.
9. Botta A, Bonifazi E, Vallo L, et al. Italian guidelines for molecular analysis in myotonic dystrophies. Acta Myol 2006;25:23-33.
10. Hammarén E, Kjellby-Wendt G, Lindberg C. Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist. Neuromuscul Disord 2005;15:610-7.
11. Kierkegaard M, Tollbäck A. Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord 2007;17:943-9.
12. Moxley RT 3rd, Logigian EL, Martens WB, et al. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve 2007;36:320-8.
13. Sansone V, Marinou K, Salvucci J, Meola G. Quantitative myotonia assessment: an experimental protocol. Neurol Sci 2000;21:S971-4.
14. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051-7.
15. Lienert GA, TESTAUFBAU UND TESTANALYSE [Test construction and analysis], 3rd edn. Weinheim: Beltz, 1969.
16. Masur H. Neurologia, Scale e Punteggi: Quantificazione di deficit neurologici. Milano: Edi-Ermes Editore, 1999.
17. Nunnally JC. Psychometric theory, 2nd edn. New York: McGraw-Hill, 1978.
18. Longstreth WT Jr, Koepsell TD, Van Belle G. Clinical neuroepidemiology. I. Diagnosis. Arch Neurol 1987;44:1091-9.
19. Bulcke JA, Termote JL, Palmers Y, Crolla D. Computed tomography of the human skeletal muscular system. Neuroradiology 1979;17:127-36.
20. Folstein MF, Folstein SE, Mchugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
21. Wechsler D. Wechsler memory scale-revised. New York: The Psychological Corp, 1987.
22. Wechsler D. The Wechsler adult intelligence scale manual. New York: The Psychological Corp., 1955.
23. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-6.
24. Dyck PJ. Quantitating severity of neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy, 3rd edn. Philadelphia: WB Saunders, 1993;686-97.
25. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J 1965;14:61-5.
26. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead mobility index: a further development of the Rivermead motor assessment. Int Disabil Stud 1991;13:50-4.
27. Suurmeijer TP, Doeglas DM, Moum T, et al. The Groningen activity restriction scale for measuring disability: its utility in international comparisons. Am J Public Health 1994;84:1270-3.
28. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
29. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378-82.
30. Fleiss JL. Measuring agreement between two judges on the presence or absence of a trait. Biometrics 1975;31:651-9.
31. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981;212-36.
32. Cronbach LJ. Coefficient alpha and the internal structure of the tests. Psychometrika 1951;16:297-334.
33. Kurihara T. New classification and treatment for myotonic disorders. Int Med 2005;44:1027-32.
34. Meola G, Sansone V. Therapy in myotonic disorders and in muscle channelopathies. Neurol Sci 2000;21:S953-61.
35. Trip J, Drost G, Van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev 2006;25:CD004762.
36. Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010;4:74.